Tackling Tuberculosis in Under-Served Populations: A Resource for TB Control Boards and their partners
Key populations brief
Accessed November 2017
PLoS ONE 12(7): e0180996. https://doi.org/10.1371/journal.pone.0180996
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Doc. No.: INS/GDL/001-(Annexes)
Supplement article
The Journal of Infectious Diseases® 2017;216(S7):S675–8
DOI: 10.1093/infdis/jix368
Finding the Missing Tuberculosis Patients • JID 2017:216 (Suppl 7) • S675
Downloaded from https://academic.oup.com/jid/article-abstract/216/suppl_7/S675/4595547
by guest on 13 Nove...mber 2017
more
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
PQDx 0179-012-00 WHO
PQDx Public Report
June/2017, version 4.0
Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Practical Guidance for collaborative interventions
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
Guidelines for treatment of drug-susceptible tuberculosis and patient care
2017 update